Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patient Receiving Immunotherapy
Vancouver, British Columbia – (June 29th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a […]
BIOMARK TEAM SECURES HEALTH CANADA LETTER OF NO OBJECTION FOR ITS GLIOBLASTOMA CLINICAL TRIAL
Vancouver, British Columbia – (August 27th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA. The company […]
BioMark Diagnostics Inc. Clarifies Prior Disclosure
Vancouver, British Columbia – (June 11 , 2020) – – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, wishes to include additional information to clarify the disclosures in its news release disseminated […]
A Good Choice for MMJ and Biotech Market Opportunity
A Good Choice for MMJ and Biotech Market Opportunity Gaalen Engen, Stockhouse.com Original article: http://www.stockhouse.com/news/newswire/2016/03/03/a-good-choice-for-mmj-and-biotech-market-opportunity For almost fifty years, his was a trusted voice when it came to sports and news. Bill Good, following in the footsteps of his father, “Breathless Bill”, established himself as a national broadcasting icon over a long career which included […]
